Phibro Animal Health (NASDAQ:PAHC) Updates FY 2027 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2027 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.410-3.590 for the period, compared to the consensus estimate of 3.340. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC traded up $0.16 on Wednesday, reaching $36.09. 296,733 shares of the company were exchanged, compared to its average volume of 295,651. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 15.49, a price-to-earnings-growth ratio of 0.50 and a beta of 0.46. Phibro Animal Health has a 1-year low of $28.25 and a 1-year high of $60.08. The company has a 50-day moving average of $33.84 and a 200-day moving average of $42.54. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, August 26th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.14. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $396.75 million during the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Equities analysts forecast that Phibro Animal Health will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be given a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a yield of 1.3%. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Finally, Citigroup cut their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $42.50.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after acquiring an additional 363 shares in the last quarter. Brooklyn Investment Group lifted its stake in Phibro Animal Health by 8.7% during the fourth quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock worth $255,000 after purchasing an additional 538 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Phibro Animal Health by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Phibro Animal Health by 8.2% in the 3rd quarter. Intech Investment Management LLC now owns 9,147 shares of the company’s stock valued at $370,000 after purchasing an additional 697 shares in the last quarter. Finally, Swiss National Bank increased its stake in shares of Phibro Animal Health by 1.8% in the 4th quarter. Swiss National Bank now owns 40,100 shares of the company’s stock valued at $1,498,000 after purchasing an additional 700 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.